Elizabeth K. Van Dril, PharmD, BCPS, BCACP, CDCES

Kidney-protective therapy is now layered. How pharmacists screen, stage by KDIGO, stagger ACE/ARB, SGLT2, GLP-1, and finerenone, and cut CV risk.

Finerenone, SGLT2s, and GLP-1s each target a different driver of CKD—pharmacists can tie every drug to a matching lifestyle change for adherence.

Chronic kidney disease (CKD) in diabetes is often caught late. Standardized eGFR and UACR screening plus thoughtful sequencing can slow progression and cut CV risk.

The current nationwide push for pharmacist provider status emphasizes an increasing need for advanced clinical training throughout the profession, and residency program curriculums are filling this need.